



Day 1: Tues 2nd Sept'14

Room: Charter 1

09:10 - 16:30

Innovations in Screening and Assay Development

The Pharmaceutical industry has faced unprecedented challenges over the last decade ranging from R&D productivity decline, loss of sales due to generic competition and tougher pricing agreements. Hence, it is now more imperative than ever to utilise screening technologies, screening paradigms and initiatives that provide the greatest probability of success for identifying lead-quality hit molecules. This session will highlight how hit identification has changed since the HTS revolution and will focus on the latest methodologies and scientific breakthroughs that provide new opportunities to drug 1. existing target classes and 2. those target classes that have so far proved largely intractable.

CHAIRS : Alan Wise, TTP and Ryan Bingham, GSK				
TIME	SPEAKER	TITLE		
9:10	Session Chairs	Introduction and Welcome		
9:15	Lorenz Mayr, Astra Zeneca	High-Throughput Screening – Challenges & Opportunities		Session Keynote
10:00	Rob Jepras, GSK	Flow cytometry as a drug screening platform		
10:30		COFFEE BREAK		
11:00	Alastair Brown, Heptares Therapeutics Ltd	Structure based GPCR drug discovery		
11:30	Poster Taster Session			
12:00	Snapshots			
12:30	LUNCH, Exhibition, Posters, Lunchtime Workshops			
2:00	Susan Galbraith, Global Head of Oncology, iMed, Astra Zeneca	Genetic drivers of cancer growth and resistance mechanisms	Plenary Keynote	In Charter 1 (here)
3:00	Darren Tomlinson, University of Leeds	Adhirons – novel tools for drug discovery		
3:30	Jonathan Wingfield, AstraZeneca	Mass Spectrometry in the Hit to Lead phase of drug discovery: Applications today and options for tomorrow.		
4:00	Ingo Kober, Merck KgaA	Primarily primary and then 3D: A full deck phenotypic HTS on primary cells and evaluation of 3D		
4:30-5:30	POSTER VIEWING			
5:00-7:00	Networking / Drinks Reception in the Exhibition hall			
5:30-7:00	DRAGONS DEN in the Exhibition hall			
Publication date 09/06/14. More detail, abstracts, speaker biogs, etc, are available on our website: www.elrig.org				





